{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of pharmacotherapy is ensuring that a sufficient amount of drug reaches its target. This exercise focuses on quantifying the total drug exposure after a single dose using the Area Under the Curve (AUC), a fundamental pharmacokinetic parameter. By working through this problem, you will not only calculate the total exposure to rifampicin, a key anti-leprosy drug, but also critically evaluate why this measure of total exposure alone is not enough to predict the drug's peak concentration and its immediate bactericidal effect. ",
            "id": "4978238",
            "problem": "A patient with multibacillary leprosy receives a supervised single oral dose of rifampicin of $600$ $\\mathrm{mg}$ as part of a standard multidrug therapy. Assume linear pharmacokinetics, negligible nonlinearities at this dose, and complete systemic availability for this dose such that the absolute bioavailability is $F=1$. The measured systemic clearance of rifampicin in this patient is $CL=12$ $\\mathrm{L/h}$. Using the foundational pharmacokinetic definitions of clearance and exposure, derive an expression for the area under the plasma concentration–time curve from time zero to infinity, $AUC_{0\\to\\infty}$, following the single dose, and compute its value. Express your final numerical answer in $\\mathrm{mg\\cdot h/L}$ and round to $3$ significant figures.\n\nThen, based on first principles and definitions, discuss whether knowing $AUC_{0\\to\\infty}$ alone is sufficient to infer that the ratio of the maximum (peak) plasma concentration to the Minimum Inhibitory Concentration, $C_{\\max}/\\mathrm{MIC}$, is high for rifampicin, where $C_{\\max}$ denotes the maximum plasma concentration and $\\mathrm{MIC}$ denotes the Minimum Inhibitory Concentration for the infecting organism. Do not perform any additional numerical calculations for this discussion.",
            "solution": "The problem is assessed to be valid as it is scientifically grounded in the principles of pharmacokinetics, is well-posed with sufficient and consistent data, and is stated in an objective, formalizable manner. We can therefore proceed with a solution.\n\nThe problem is divided into two parts. The first part requires the derivation of an expression for the area under the plasma concentration–time curve from time zero to infinity, $AUC_{0\\to\\infty}$, and the calculation of its numerical value for a given dose of rifampicin. The second part is a conceptual question about the relationship between $AUC_{0\\to\\infty}$ and the peak plasma concentration, $C_{\\max}$.\n\n**Part 1: Derivation and Calculation of $AUC_{0\\to\\infty}$**\n\nWe begin with the fundamental definition of systemic clearance ($CL$). Systemic clearance is a pharmacokinetic parameter that describes the volume of biological fluid (e.g., plasma) cleared of a drug per unit of time. It relates the rate of drug elimination from the body to the drug's concentration in plasma, $C(t)$. For a drug exhibiting linear pharmacokinetics, $CL$ is a constant. The rate of elimination at any time $t$ is given by:\n$$\n\\text{Rate of elimination} = CL \\cdot C(t)\n$$\nThe total amount of drug eliminated from the body over all time, from administration ($t=0$) to a time far in the future ($t=\\infty$), is the integral of this elimination rate over that time interval.\n$$\n\\text{Total amount eliminated} = \\int_{0}^{\\infty} (CL \\cdot C(t)) \\, dt\n$$\nSince the problem states to assume linear pharmacokinetics, $CL$ is a constant and can be moved outside the integral:\n$$\n\\text{Total amount eliminated} = CL \\cdot \\int_{0}^{\\infty} C(t) \\, dt\n$$\nThe integral $\\int_{0}^{\\infty} C(t) \\, dt$ is, by definition, the area under the plasma concentration–time curve from time zero to infinity, denoted as $AUC_{0\\to\\infty}$. Therefore:\n$$\n\\text{Total amount eliminated} = CL \\cdot AUC_{0\\to\\infty}\n$$\nAccording to the principle of mass balance, the total amount of drug eliminated from the body must be equal to the total amount of drug that reaches the systemic circulation. The latter is known as the systemically available dose, which is the product of the administered dose ($\\text{Dose}$) and the absolute bioavailability ($F$).\n$$\n\\text{Total amount systemically available} = F \\cdot \\text{Dose}\n$$\nBy equating the total amount of drug that enters the systemic circulation with the total amount that is eliminated from it, we obtain the foundational relationship:\n$$\nF \\cdot \\text{Dose} = CL \\cdot AUC_{0\\to\\infty}\n$$\nThis equation provides a model-independent way to relate dose, bioavailability, clearance, and total drug exposure. To find the expression for $AUC_{0\\to\\infty}$, we rearrange this equation:\n$$\nAUC_{0\\to\\infty} = \\frac{F \\cdot \\text{Dose}}{CL}\n$$\nThis is the derived expression for the area under the curve.\n\nNow, we compute its numerical value using the provided data:\n- Administered dose, $\\text{Dose} = 600 \\, \\mathrm{mg}$\n- Absolute bioavailability, $F = 1$ (unitless)\n- Systemic clearance, $CL = 12 \\, \\mathrm{L/h}$\n\nSubstituting these values into the derived expression:\n$$\nAUC_{0\\to\\infty} = \\frac{1 \\cdot 600 \\, \\mathrm{mg}}{12 \\, \\mathrm{L/h}}\n$$\n$$\nAUC_{0\\to\\infty} = 50 \\, \\mathrm{mg\\cdot h/L}\n$$\nThe problem requires the answer to be rounded to $3$ significant figures. To express $50$ with three significant figures, we write it as $50.0$.\n$$\nAUC_{0\\to\\infty} = 50.0 \\, \\mathrm{mg\\cdot h/L}\n$$\n\n**Part 2: Sufficiency of $AUC_{0\\to\\infty}$ for Inferring $C_{\\max}/\\mathrm{MIC}$**\n\nThe second part of the problem asks whether knowing $AUC_{0\\to\\infty}$ alone is sufficient to infer that the ratio of the maximum plasma concentration to the Minimum Inhibitory Concentration, $C_{\\max}/\\mathrm{MIC}$, is high for rifampicin.\n\nThe answer is no. Knowing the value of $AUC_{0\\to\\infty}$ alone is insufficient to determine $C_{\\max}$ and therefore the ratio $C_{\\max}/\\mathrm{MIC}$. This conclusion is based on the following pharmacokinetic principles:\n\n1.  **$AUC$ versus $C_{\\max}$**: $AUC_{0\\to\\infty}$ represents the total or cumulative *extent* of systemic drug exposure over time. As derived above, it is determined solely by the bioavailable dose ($F \\cdot \\text{Dose}$) and the body's ability to eliminate the drug ($CL$). In contrast, $C_{\\max}$ represents the peak or maximum concentration achieved in the plasma after administration. $C_{\\max}$ is determined not only by the extent of absorption but also, critically, by the *rate* of absorption and the *rate* of drug distribution and elimination.\n\n2.  **Dependence on Absorption Rate ($k_a$)**: The rate at which the drug is absorbed from the site of administration (e.g., the gastrointestinal tract for an oral dose) into the systemic circulation has a profound effect on $C_{\\max}$ but does not affect the total $AUC_{0\\to\\infty}$ (assuming bioavailability $F$ remains unchanged). A rapid absorption (high absorption rate constant, $k_a$) will lead to a higher $C_{\\max}$ that occurs earlier in time. A slow absorption (low $k_a$), as might be seen with an extended-release formulation, will result in a lower $C_{\\max}$ that occurs later. Two different oral formulations of the same drug and dose can have identical $AUC_{0\\to\\infty}$ values but vastly different $C_{\\max}$ values. Since $AUC_{0\\to\\infty}$ provides no information about $k_a$, it cannot be used to determine $C_{\\max}$.\n\n3.  **Dependence on Volume of Distribution ($V_d$)**: The apparent volume of distribution ($V_d$) is another fundamental pharmacokinetic parameter that relates the amount of drug in the body to the concentration in the plasma. Plasma concentration at any time, including $C_{\\max}$, is inversely related to $V_d$. A drug with a large $V_d$ distributes extensively into tissues, resulting in lower plasma concentrations for a given dose compared to a drug with a small $V_d$. The systemic clearance ($CL$) and the volume of distribution ($V_d$) are independent primary parameters. The formula $AUC_{0\\to\\infty} = (F \\cdot \\text{Dose})/CL$ is independent of $V_d$. Therefore, two drugs could have the same dose, bioavailability, and clearance (and thus the same $AUC_{0\\to\\infty}$), but if they have different volumes of distribution, their $C_{\\max}$ values will differ. Knowing $AUC_{0\\to\\infty}$ provides no information about $V_d$.\n\nIn summary, $C_{\\max}$ is a function of multiple parameters, including the dose, bioavailability, absorption rate constant, volume of distribution, and elimination rate constant ($k_e = CL/V_d$). The expression for $AUC_{0\\to\\infty}$ depends only on the bioavailable dose and clearance. Because $AUC_{0\\to\\infty}$ is independent of the absorption rate ($k_a$) and the volume of distribution ($V_d$), which are critical determinants of $C_{\\max}$, knowledge of $AUC_{0\\to\\infty}$ alone is fundamentally insufficient to infer the value of $C_{\\max}$ or the pharmacodynamic ratio $C_{\\max}/\\mathrm{MIC}$.",
            "answer": "$$\n\\boxed{50.0}\n$$"
        },
        {
            "introduction": "Effective pharmacotherapy requires not only understanding drug levels but also accurately monitoring the patient's response to treatment. In leprosy, this involves interpreting specialized bacteriological indices from skin smears, a task that can be complicated by the body's own immune reactions. This practice presents a realistic clinical scenario that will teach you how to interpret the Bacterial Index (BI) and Morphological Index (MI) to confirm treatment success, and how to distinguish this from an immunological complication that can mimic a relapse. ",
            "id": "4978224",
            "problem": "A $28$-year-old man with multibacillary leprosy has completed $12$ months of World Health Organization (WHO) Multidrug Therapy (MDT) consisting of monthly rifampicin and daily dapsone plus clofazimine. At baseline, his slit-skin smear Bacterial Index (BI, Ridley scale) was $4$ and Morphological Index (MI) was $20\\%$. At $12$ months, repeat slit-skin smears show BI $= 3$ and MI $= 0\\%$. He is clinically improved but has developed tender erythematous nodules on the extensor surfaces over the past $3$ weeks. Ziehl–Neelsen staining of a new lesion demonstrates numerous acid-fast bacilli. The treating team is concerned about “persisting bacilli” and wonders whether this represents treatment failure.\n\nFrom the standpoint of pharmacology and pathophysiology, choose the statement(s) that best explain the persistence of bacilli in lesions after effective therapy and appropriately prevent overinterpretation of clinical nodules as failure, while proposing objective criteria for cure.\n\nA. Any post-treatment acid-fast positivity on skin smears necessarily indicates viable bacilli and pharmacological failure.\n\nB. A rapid fall of the Morphological Index to $0\\%$ with a slower decline in Bacterial Index is compatible with cure, because dead bacilli can remain acid-fast and be cleared slowly by host cells.\n\nC. Tender erythematous nodules during or after MDT should be classified as relapse unless polymerase chain reaction (PCR) for Mycobacterium leprae DNA is negative.\n\nD. Objective criteria for cure include completion of WHO MDT of appropriate duration, absence of new nerve function impairment, MI $= 0\\%$ on consecutive smears, and a downward trend in BI of approximately $1$ $\\log_{10}$ unit per year.\n\nE. Persistence of nodules mandates extension of MDT beyond $24$ months in all multibacillary cases.\n\nF. In endemic settings, mouse footpad growth remains the routine criterion to declare cure and should be performed for all suspected failures.",
            "solution": "## Problem Validation\n\n### Step 1: Extract Givens\n- Patient: A $28$-year-old man with multibacillary (MB) leprosy.\n- Treatment History: Completed $12$ months of World Health Organization (WHO) Multidrug Therapy (MDT) consisting of monthly rifampicin and daily dapsone plus clofazimine.\n- Baseline Bacteriology (time = $0$): Slit-skin smear Bacterial Index (BI, Ridley scale) was $4$. Morphological Index (MI) was $20\\%$.\n- Follow-up Bacteriology (time = $12$ months): Slit-skin smear BI = $3$ and MI = $0\\%$.\n- Clinical Status at $12$ months: He is clinically improved but has developed tender erythematous nodules on the extensor surfaces over the past $3$ weeks.\n- Biopsy Result: Ziehl–Neelsen staining of a new lesion demonstrates numerous acid-fast bacilli.\n- Central Question: The problem asks for the statement(s) that best explain the persistence of bacilli and define objective criteria for cure, to avoid misinterpreting the clinical nodules as treatment failure.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is scientifically grounded, well-posed, and objective.\n- **Scientific Grounding**: The scenario is a classic and realistic representation of a common challenge in the management of multibacillary leprosy. The patient's diagnosis, the WHO-MDT regimen, the bacteriological indices (BI and MI), their evolution over time, and the development of tender erythematous nodules are all consistent with established medical literature in leprology. The phenomenon described is a Type $2$ Lepra Reaction (Erythema Nodosum Leprosum, or ENL), an immunological complication, not a sign of pharmacological failure.\n- **Well-Posedness**: The problem provides sufficient, consistent data to evaluate the provided options against current principles of pharmacology and pathophysiology. A logical and definitive conclusion can be reached for each option.\n- **Objectivity**: The description of the clinical and laboratory findings is factual and devoid of subjective or ambiguous language.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A detailed solution will be derived.\n\n## Solution Derivation\n\nThe clinical scenario presents a patient with multibacillary leprosy who has successfully completed a standard $12$-month course of WHO MDT. The core of the problem is to correctly interpret the post-treatment findings.\n\n1.  **Bacteriological Indices Interpretation**:\n    *   The **Bacterial Index (BI)** is a logarithmic measure of the density of *Mycobacterium leprae* in tissue, as visualized on a slit-skin smear. It quantifies both living and dead bacilli, as the Ziehl–Neelsen (acid-fast) stain colors the mycolic acid in the cell wall, which persists long after the bacterium has died. The patient's BI decreased from $4$ to $3$ over $12$ months. This represents a $1$-log reduction, which is an expected and satisfactory rate of clearance. The host's macrophages slowly clear the vast number of dead bacilli, a process that can take many years.\n    *   The **Morphological Index (MI)** is the percentage of bacilli that appear \"solid-staining\" and morphologically intact, which is the best microscopic correlate of viability. A rapid fall in the MI is the primary indicator of an effective bactericidal drug regimen. The patient's MI fell from $20\\%$ to $0\\%$. An MI of $0\\%$ is the hallmark of successful chemotherapy, indicating that no viable-appearing bacilli could be detected.\n\n2.  **Clinical Manifestations Interpretation**:\n    *   The patient is \"clinically improved,\" which supports the conclusion of successful treatment.\n    *   The new \"tender erythematous nodules\" are a classic presentation of **Erythema Nodosum Leprosum (ENL)**, or a **Type 2 Lepra Reaction**. This is an immune-complex-mediated inflammatory reaction (a type III hypersensitivity reaction) triggered by antigens released from the massive number of dead and dying *M. leprae* bacilli. It characteristically occurs in patients with a high bacterial load (MB leprosy) and typically presents during or after the completion of MDT. The finding of numerous acid-fast bacilli in these lesions is expected, as these dead bacilli are the antigenic stimulus. ENL is not a sign of treatment failure or relapse but an immunological complication that requires anti-inflammatory treatment (e.g., corticosteroids, thalidomide), not an extension or change of anti-leprosy drugs.\n\nBased on this understanding, we can now evaluate each statement.\n\n### Option-by-Option Analysis\n\n**A. Any post-treatment acid-fast positivity on skin smears necessarily indicates viable bacilli and pharmacological failure.**\nThis statement is fundamentally incorrect. The acid-fast property of mycobacteria is due to the lipid-rich mycolic acid cell wall. This structure is very stable and remains intact long after metabolic activity has ceased and the bacterium is dead. Therefore, Ziehl–Neelsen staining cannot differentiate between live and dead bacilli. The BI measures the total load of acid-fast bacilli, and it is expected to remain positive for years after successful treatment. The MI, not the BI or simple acid-fast positivity, is used to assess viability.\n**Verdict: Incorrect.**\n\n**B. A rapid fall of the Morphological Index to $0\\%$ with a slower decline in Bacterial Index is compatible with cure, because dead bacilli can remain acid-fast and be cleared slowly by host cells.**\nThis statement is a precise and accurate description of the expected bacteriological response to effective MDT in a patient with multibacillary leprosy. The potent bactericidal activity of rifampicin causes a rapid killing of bacilli, leading to a quick drop in the MI to $0\\%$. The anatomical clearance of the resulting bacillary debris by the host's immune system is a much slower process, reflected in the gradual decline of the BI. This discrepancy in the rates of decline of MI and BI is the classic sign of a favorable treatment response.\n**Verdict: Correct.**\n\n**C. Tender erythematous nodules during or after MDT should be classified as relapse unless polymerase chain reaction (PCR) for Mycobacterium leprae DNA is negative.**\nThis statement is incorrect. The nodules are characteristic of ENL, an immune reaction, not a relapse of the infection. Furthermore, standard PCR detects DNA sequences. DNA is a stable molecule that, like the cell wall, can persist in tissue long after the organism is non-viable. A positive PCR for *M. leprae* DNA does not prove the presence of live bacteria and is therefore not a reliable marker for relapse. Using this criterion would lead to the misdiagnosis of immunological reactions as treatment failures.\n**Verdict: Incorrect.**\n\n**D. Objective criteria for cure include completion of WHO MDT of appropriate duration, absence of new nerve function impairment, MI $= 0\\%$ on consecutive smears, and a downward trend in BI of approximately $1$ $\\log_{10}$ unit per year.**\nThis statement provides a comprehensive and clinically sound set of criteria for defining cure in leprosy. Each component is critical:\n- Completion of the prescribed MDT regimen is the foundational therapeutic milestone.\n- Absence of new nerve damage is a key clinical indicator of disease inactivity.\n- An MI of $0\\%$ confirms the bactericidal efficacy of the treatment.\n- A steady, slow decline in the BI (at a rate of about $0.5$ to $1$ log unit/year) confirms that the bacillary load is decreasing as expected and not replenishing itself.\nThese criteria collectively provide a robust framework for distinguishing a cured patient (who may still have immune reactions) from one who has relapsed. The patient in the scenario fits these criteria for cure.\n**Verdict: Correct.**\n\n**E. Persistence of nodules mandates extension of MDT beyond $24$ months in all multibacillary cases.**\nThis is incorrect. The nodules are a manifestation of ENL, an inflammatory condition. The treatment for ENL is immunomodulatory/anti-inflammatory therapy. Extending the antibiotic MDT is not indicated, as the infection has already been controlled (MI=$0\\%$), and it would not alleviate the inflammatory symptoms of ENL. Such a practice would lead to unnecessary drug exposure and costs.\n**Verdict: Incorrect.**\n\n**F. In endemic settings, mouse footpad growth remains the routine criterion to declare cure and should be performed for all suspected failures.**\nThis statement is incorrect. Inoculation of bacilli into the mouse footpad (MFP) is the \"gold standard\" for assessing the viability of *M. leprae* in a research setting. However, it is a complex, expensive, and protracted procedure (taking $6-12$ months to yield a result) that is only available in specialized reference laboratories. It is by no means a \"routine criterion\" for clinical management or declaring cure. It is reserved for select cases of suspected drug resistance or scientifically ambiguous relapse, not for a classic scenario of ENL post-treatment.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{BD}$$"
        },
        {
            "introduction": "The principles of pharmacology have profound implications for public health strategy, particularly in the fight against antimicrobial resistance. This final practice moves from the individual patient to the bacterial population, using a mathematical model to explore the dynamics of drug resistance. By applying the concept of mutation-selection balance, you will gain a quantitative understanding of why Multi-Drug Therapy (MDT) is not just a clinical recommendation but a critical public health tool for preventing the emergence and spread of dapsone-resistant *Mycobacterium leprae*. ",
            "id": "4978208",
            "problem": "A public health program for Hansen’s disease (leprosy) transitions from historical dapsone monotherapy to modern Multi-Drug Therapy (MDT). You are asked to estimate the expected equilibrium prevalence of dapsone-resistant alleles in the bacterial population of Mycobacterium leprae using mutation–selection balance under two environmental classes: inappropriate monotherapy and correct MDT.\n\nAssume the following scientifically standard bases:\n- In a large, haploid, clonally reproducing population with forward mutation rate $\\,\\mu\\,$ per genome per generation to a resistant allele, and a constant selection coefficient $\\,s\\,$ against that resistant allele in a given environment (so the resistant genotype has relative fitness $\\,1 - s\\,$ and the wild type has relative fitness $\\,1\\,$), a mutation–selection equilibrium can arise when $\\,\\mu \\ll 1\\,$ and $\\,s > 0\\,$.\n- Let the fraction of bacterial generations occurring under inappropriate monotherapy be $\\,p\\,$ and under MDT be $\\,1-p\\,$. Assume rapid mixing across hosts so that the overall expected prevalence of resistance is the weighted average across these two environmental classes at their respective equilibria.\n\nIn this setting, due to adherence gaps and the intrinsic fitness cost of resistance, the net selection coefficient against resistance during inappropriate monotherapy is empirically small but positive, $\\,s_{\\mathrm{mono}} = 5 \\times 10^{-6}\\,$. Under MDT, the combined regimen eliminates any advantage of resistance to dapsone and amplifies fitness costs, yielding $\\,s_{\\mathrm{MDT}} = 2 \\times 10^{-3}\\,$. The forward mutation rate to resistance is $\\,\\mu = 2 \\times 10^{-8}\\,$, and the fraction of bacterial generations under inappropriate monotherapy is $\\,p = 1 \\times 10^{-1}\\,$.\n\nUsing only the above fundamental framework, derive from first principles the expected overall equilibrium prevalence of dapsone-resistant alleles across the entire bacterial population as a decimal fraction. Round your final answer to three significant figures. Express the final result with no units.",
            "solution": "The problem asks for the expected overall equilibrium prevalence of dapsone-resistant alleles in a *Mycobacterium leprae* population under a mixed environment of inappropriate monotherapy and correct Multi-Drug Therapy (MDT). The solution will be derived from the first principles of mutation-selection balance.\n\nFirst, let us establish the fundamental model for mutation-selection balance in a large, haploid, clonally reproducing population. Let $q$ be the frequency of a mutant allele (in this case, the dapsone-resistant allele) and $1-q$ be the frequency of the wild-type allele. The forward mutation rate from wild-type to the mutant allele is given as $\\mu$ per generation. The selection coefficient against the mutant allele is $s$, so its relative fitness is $1-s$ compared to the wild-type fitness of $1$.\n\nThe change in the frequency of the resistant allele, $\\Delta q$, in one generation is the sum of the increase due to mutation and the decrease due to selection.\n\nThe increase due to mutation, $\\Delta q_{\\text{mut}}$, arises from wild-type bacteria mutating into resistant ones. This is given by the mutation rate multiplied by the frequency of the wild-type population:\n$$\n\\Delta q_{\\text{mut}} = \\mu (1-q)\n$$\n\nThe change due to selection, $\\Delta q_{\\text{sel}}$, is determined by the differential survival of the resistant and wild-type alleles. After one generation of selection, the frequency of the resistant allele, $q'$, is its initial frequency $q$ times its relative fitness $1-s$, divided by the mean fitness of the population, $\\bar{w}$.\n$$\n\\bar{w} = q(1-s) + (1-q)(1) = 1 - sq\n$$\nThus, the frequency after selection is:\n$$\nq' = \\frac{q(1-s)}{\\bar{w}} = \\frac{q(1-s)}{1 - sq}\n$$\nThe change in frequency due to selection is:\n$$\n\\Delta q_{\\text{sel}} = q' - q = \\frac{q(1-s)}{1 - sq} - q = \\frac{q(1-s) - q(1 - sq)}{1 - sq} = \\frac{q - qs - q + sq^2}{1 - sq} = \\frac{-qs + sq^2}{1 - sq} = \\frac{-sq(1-q)}{1 - sq}\n$$\n\nAt equilibrium, the total change in allele frequency per generation is zero, i.e., $\\Delta q = \\Delta q_{\\text{mut}} + \\Delta q_{\\text{sel}} = 0$.\n$$\n\\mu(1-q) + \\frac{-sq(1-q)}{1 - sq} = 0\n$$\nSince the equilibrium frequency $q_{\\text{eq}}$ is expected to be small and not equal to $1$, we can divide by the term $(1-q)$:\n$$\n\\mu = \\frac{sq}{1 - sq}\n$$\nSolving for $q$, we get:\n$$\n\\mu(1-sq) = sq \\implies \\mu - \\mu sq = sq \\implies \\mu = sq + \\mu sq = q(s + \\mu s)\n$$\nThe exact equilibrium frequency, $q_{\\text{eq}}$, is:\n$$\nq_{\\text{eq}} = \\frac{\\mu}{s(1+\\mu)}\n$$\nThe problem states that we are in a regime where $\\mu \\ll 1$. In this case, the term $(1+\\mu) \\approx 1$, and the expression for the equilibrium frequency simplifies to the standard approximation:\n$$\nq_{\\text{eq}} \\approx \\frac{\\mu}{s}\n$$\nThis formula provides the equilibrium prevalence of the resistant allele in a single, constant environment.\n\nThe problem describes two distinct environmental classes: inappropriate monotherapy and correct MDT, each with its own selection coefficient. Let $q_{\\text{mono}}$ and $q_{\\text{MDT}}$ be the equilibrium allele prevalences in these respective environments.\n\nFor the monotherapy environment, the selection coefficient is $s_{\\text{mono}} = 5 \\times 10^{-6}$. The equilibrium prevalence is:\n$$\nq_{\\text{mono}} \\approx \\frac{\\mu}{s_{\\text{mono}}}\n$$\n\nFor the MDT environment, the selection coefficient is $s_{\\text{MDT}} = 2 \\times 10^{-3}$. The equilibrium prevalence is:\n$$\nq_{\\text{MDT}} \\approx \\frac{\\mu}{s_{\\text{MDT}}}\n$$\n\nThe problem states that the overall expected equilibrium prevalence, $q_{\\text{overall}}$, is the weighted average of the prevalences in these two environments. The weights are the fraction of bacterial generations occurring under each condition, given as $p$ for monotherapy and $1-p$ for MDT.\n$$\nq_{\\text{overall}} = p \\cdot q_{\\text{mono}} + (1-p) \\cdot q_{\\text{MDT}}\n$$\nSubstituting the expressions for $q_{\\text{mono}}$ and $q_{\\text{MDT}}$:\n$$\nq_{\\text{overall}} \\approx p \\left(\\frac{\\mu}{s_{\\text{mono}}}\\right) + (1-p) \\left(\\frac{\\mu}{s_{\\text{MDT}}}\\right)\n$$\nWe can factor out the mutation rate $\\mu$:\n$$\nq_{\\text{overall}} \\approx \\mu \\left(\\frac{p}{s_{\\text{mono}}} + \\frac{1-p}{s_{\\text{MDT}}}\\right)\n$$\n\nNow, we substitute the given numerical values into this expression:\n$\\mu = 2 \\times 10^{-8}$\n$p = 1 \\times 10^{-1} = 0.1$\n$1-p = 1 - 0.1 = 0.9$\n$s_{\\text{mono}} = 5 \\times 10^{-6}$\n$s_{\\text{MDT}} = 2 \\times 10^{-3}$\n\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) \\left(\\frac{0.1}{5 \\times 10^{-6}} + \\frac{0.9}{2 \\times 10^{-3}}\\right)\n$$\nFirst, we evaluate the terms inside the parentheses:\n$$\n\\frac{0.1}{5 \\times 10^{-6}} = \\frac{1 \\times 10^{-1}}{5 \\times 10^{-6}} = \\frac{1}{5} \\times 10^{5} = 0.2 \\times 10^{5} = 2 \\times 10^{4}\n$$\n$$\n\\frac{0.9}{2 \\times 10^{-3}} = 0.45 \\times 10^{3} = 450\n$$\nNow, substitute these back into the expression for $q_{\\text{overall}}$:\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) \\left(2 \\times 10^{4} + 450\\right)\n$$\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) (20000 + 450) = (2 \\times 10^{-8}) (20450)\n$$\n$$\nq_{\\text{overall}} \\approx (2 \\times 10^{-8}) (2.045 \\times 10^{4})\n$$\n$$\nq_{\\text{overall}} \\approx (2 \\times 2.045) \\times 10^{-8+4} = 4.09 \\times 10^{-4}\n$$\n\nThe expected overall equilibrium prevalence of dapsone-resistant alleles across the entire bacterial population is $4.09 \\times 10^{-4}$. The problem asks for this as a decimal fraction rounded to three significant figures. The calculated value $4.09 \\times 10^{-4}$ is already in scientific notation with three significant figures. As a decimal, this is $0.000409$.",
            "answer": "$$\\boxed{4.09 \\times 10^{-4}}$$"
        }
    ]
}